PMID- 19383369
OWN - NLM
STAT- MEDLINE
DCOM- 20090720
LR  - 20211203
IS  - 1878-0261 (Electronic)
IS  - 1574-7891 (Print)
IS  - 1574-7891 (Linking)
VI  - 3
IP  - 1
DP  - 2009 Feb
TI  - Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
PG  - 77-83
LID - 10.1016/j.molonc.2008.10.004 [doi]
AB  - We investigated the pro-inflammatory response mediated by TNFalpha in 
      glioblastoma and whether treatment with organoselenium Ebselen 
      (2-phenyl-1,2-benzisoselenazol-3[2H]one) can affect TNFalpha induced inflammatory 
      response. Exposure to TNFalpha increased the expression of pro-inflammatory 
      mediator interleukin IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1) and 
      cyclooxygenase (COX-2). Treatment with Ebselen abrogated TNFalpha induced 
      increase in pro-inflammatory mediators. Ebselen not only abrogated TNFalpha 
      induced enhanced invasiveness of glioma cells by down-regulating matrix metallo 
      proteinase (MMP-9) and urokinase plasminogen (uPa) activity, but also inhibited 
      glioma cell migration. Treatment with Ebselen also down-regulated the enhanced 
      ROS production of TNFalpha treated glioma cells. In addition, Ebselen induced DNA 
      damage repair signaling response in glioma cells both in the presence and absence 
      of TNFalpha. These studies indicate that together with its known ability to 
      sensitize glioma cell to TNFalpha induced apoptosis, Ebselen can overcome 
      TNFalpha induced pro-inflammatory mediators to prevent a build up of a 
      deleterious pro-inflammatory tumor microenvironment.
FAU - Tewari, Richa
AU  - Tewari R
AD  - National Brain Research Centre, Manesar, Gurgaon, Haryana 122 050, India.
FAU - Sharma, Vivek
AU  - Sharma V
FAU - Koul, Nitin
AU  - Koul N
FAU - Ghosh, Abhishek
AU  - Ghosh A
FAU - Joseph, Christy
AU  - Joseph C
FAU - Hossain Sk, Ugir
AU  - Hossain Sk U
FAU - Sen, Ellora
AU  - Sen E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081105
PL  - United States
TA  - Mol Oncol
JT  - Molecular oncology
JID - 101308230
RN  - 0 (Azoles)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Isoindoles)
RN  - 0 (Organoselenium Compounds)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 40X2P7DPGH (ebselen)
SB  - IM
MH  - Azoles/*pharmacology/therapeutic use
MH  - Cell Movement/drug effects
MH  - DNA Repair
MH  - Gene Expression Regulation/drug effects
MH  - Glioblastoma/*pathology
MH  - Humans
MH  - Inflammation/chemically induced/*drug therapy
MH  - Inflammation Mediators/analysis
MH  - Isoindoles
MH  - Organoselenium Compounds/*pharmacology/therapeutic use
MH  - Tumor Necrosis Factor-alpha/*pharmacology
PMC - PMC5527871
EDAT- 2009/04/23 09:00
MHDA- 2009/07/21 09:00
PMCR- 2009/02/01
CRDT- 2009/04/23 09:00
PHST- 2008/06/03 00:00 [received]
PHST- 2008/09/24 00:00 [revised]
PHST- 2008/10/15 00:00 [accepted]
PHST- 2009/04/23 09:00 [entrez]
PHST- 2009/04/23 09:00 [pubmed]
PHST- 2009/07/21 09:00 [medline]
PHST- 2009/02/01 00:00 [pmc-release]
AID - S1574-7891(08)00129-4 [pii]
AID - MOL220093177 [pii]
AID - 10.1016/j.molonc.2008.10.004 [doi]
PST - ppublish
SO  - Mol Oncol. 2009 Feb;3(1):77-83. doi: 10.1016/j.molonc.2008.10.004. Epub 2008 Nov 
      5.